NCT06157580CompletedEarly phase 1
Balance of Angiotensin II Receptors in Vessel Function After Preeclampsia
Source: ClinicalTrials.gov · Last updated 24 Dec 2024
Brief summary (registry, in English)
Otherwise healthy women who develop preeclampsia during pregnancy are more likely to develop and die of cardiovascular disease later in life. The reason why this occurs is unclear but may be related to impaired endothelial function and dysregulation of the angiotensin system that occurs during preeclampsia and persists postpartum, despite the remission of clinical symptoms. The purpose of this investigation is to determine the mechanisms contributing to this lasting blood vessel damage caused by reduced endothelial function in women who have had preeclampsia compared to women who had a healthy pregnancy. Identification of these mechanisms and treatment strategies may lead to better clinical management of cardiovascular disease risk in these women. The purpose of this study is to examine differences in the microvascular balance of angiotensin II receptors women who have had preeclampsia. This will help the investigators better understand the mechanisms of dysregulated angiotensin II receptors in formerly preeclamptic women, and how activation or inhibition of these receptors may restore microvascular function. In this study, the investigators use the blood vessels in the skin as a representative vascular bed for examining mechanisms of microvascular dysfunction in humans. Using a minimally invasive technique (intradermal microdialysis for the local delivery of pharmaceutical agents) the investigators examine the blood vessels in a dime-sized area of the skin.
- Status (registry)
- Completed
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- First submitted
- 27 Nov 2023
- Start date
- 8 Dec 2023
- Primary completion date
- 24 Oct 2024
- Lead sponsor
- Anna Stanhewicz, PhD
- NCT number
- NCT06157580
What you commit to
- Study type: Interventional · Early phase 1
- Participants enrolled: 24
- From 8 Dec 2023 to the primary completion date, 24 Oct 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- current antihypertensive medication
- statin or other cholesterol-lowering medication
Other illness
- history of hypertension or metabolic disease before pregnancy
- history of gestational diabetes or gestational hypertension
- skin diseases
- allergy to materials used during the experiment.(e.g. latex),
- known allergy to study drugs
Other
- current tobacco use
- currently pregnant or planning to become pregnant
- body mass index less than \<18.5 or \>30 kg/m2
Who the study is looking for
- women who had preeclampsia and women who did not have preeclampsia
- 12 weeks to 5 years postpartum
- 18-45 years old
Age in the registry: 18 years to 45 years · Sex: Female · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Iowa Coordinator of this site? Confirm its status | Iowa City | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.